Association between change in HDL-C and vascular events in patients treated with statins Report from the UK general practice research database英文文献资料.docVIP

World Journal of Cardiovascular Diseases, 2012, 2, 64-73 WJCD /10.4236/wjcd.2012.22011 Published Online April 2012 (http://www.SciRP.org/journal/wjcd/) Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database Lori D. Bash , Tun-Ying Hsu , Vasilisa Sazonov , Baishali Ambegaonkar 1 2 1 1 1 2 Global Health Outcomes, Merck Co., Inc., Whitehouse Station, USA Department of Epidemiology, University of Medicine and Dentistry of New Jersey, Piscataway, USA Email: tun-ying.hsu@ Received 13 January 2012; revised 17 February 2012; accepted 25 February 2012 ABSTRACT crease HDL-C could benefit patients by reducing the risk of CV/CB events. Dyslipidemia, including low levels of high-density lipoprotein cholesterol (HDL-C), is a relatively well- established risk factor for cardiovascular disease. How- ever, the independent association between changes in HDL-C and the subsequent risk of cardiovascular events has not been well studied. The retrospective cohort analysis was conducted to evaluate the asso- ciation between changes in HDL-C and cardiovascu- lar (CV) and/or cerebrovascular (CB) events among statin-treated patients. Patient demographics, clinical characteristics, laboratory data, and CV/CB events, were collected from the UK General Practice Re- search Database. The association between the risk of an incident event and changes in patients’ HDL-C was estimated using multivariate Cox proportional hazards models. Among 17,923 statin-treated patients with an average follow-up of 1.9 years, there were 815 CV events and 220 CB events. The average change in HDL-C experienced was 0.4 mg/dL, ranging from 11 mg/dL average decrease in the lowest change quartile to 12 mg/dL a